Improving Influenza HA-Vlps Production in Insect High Five Cells via Adaptive Laboratory Evolution.
adaptive laboratory evolution
baculovirus expression system
improved production
influenza HA-VLPs
insect High Five cells
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
07
09
2020
revised:
28
09
2020
accepted:
05
10
2020
entrez:
10
10
2020
pubmed:
11
10
2020
medline:
11
10
2020
Statut:
epublish
Résumé
The use of non-standard culture conditions has proven efficient to increase cell performance and recombinant protein production in different cell hosts. However, the establishment of high-producing cell populations through adaptive laboratory evolution (ALE) has been poorly explored, in particular for insect cells. In this study, insect High Five cells were successfully adapted to grow at a neutral culture pH (7.0) through ALE for an improved production of influenza hemagglutinin (HA)-displaying virus-like particles (VLPs). A stepwise approach was used for the adaptation process, in which the culture pH gradually increased from standard 6.2 to 7.0 (ΔPh = 0.2-0.3), and cells were maintained at each pH value for 2-3 weeks until a constant growth rate and a cell viability over 95% were observed. These adapted cells enabled an increase in cell-specific HA productivity up to three-fold and volumetric HA titer of up to four-fold as compared to non-adapted cells. Of note, the adaptation process is the element driving increased specific HA productivity as a pH shift alone was inefficient at improving productivities. The production of HA-VLPs in adapted cells was successfully demonstrated at the bioreactor scale. The produced HA-VLPs show the typical size and morphology of influenza VLPs, thus confirming the null impact of the adaptation process and neutral culture pH on the quality of HA-VLPs produced. This work strengthens the potential of ALE as a bioprocess engineering strategy to improve the production of influenza HA-VLPs in insect High Five cells.
Identifiants
pubmed: 33036359
pii: vaccines8040589
doi: 10.3390/vaccines8040589
pmc: PMC7711658
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : SFRH/BD/134107/2017
Organisme : Fundação para a Ciência e a Tecnologia
ID : FRH/BD/138937/2018
Organisme : Fundação para a Ciência e a Tecnologia
ID : IF/01704/2014
Organisme : Fundação para a Ciência e a Tecnologia
ID : IF/01704/2014/CP1229/CT0001
Organisme : European Commission
ID : FP7-HEALTH-2013-INNOVATION-1, GA n. 602640
Références
Metab Eng. 2017 Jan;39:141-150
pubmed: 27908688
Mol Syst Biol. 2010 Dec 21;6:449
pubmed: 21179021
Commun Biol. 2019 Apr 26;2:144
pubmed: 31044169
Bioprocess Biosyst Eng. 2013 Nov;36(11):1571-7
pubmed: 23423557
Expert Rev Vaccines. 2013 Feb;12(2):225-36
pubmed: 23414412
PLoS One. 2014 Apr 08;9(4):e94401
pubmed: 24713807
J Biotechnol. 2003 May 8;102(3):291-300
pubmed: 12730004
Biomed Res Int. 2015;2015:504831
pubmed: 25815321
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1904-E1912
pubmed: 28202733
Appl Microbiol Biotechnol. 1993 Feb;38(5):619-23
pubmed: 7763472
PLoS One. 2014 Nov 17;9(11):e112777
pubmed: 25402470
Appl Microbiol Biotechnol. 2003 Jul;62(1):1-20
pubmed: 12733003
Bioconjug Chem. 2016 Oct 19;27(10):2386-2399
pubmed: 27652605
Biotechniques. 2003 Feb;34(2):260-2, 264
pubmed: 12613247
Biotechnol J. 2010 Jan;5(1):17-23
pubmed: 20041443
J Virol Methods. 2009 Jul;159(1):69-80
pubmed: 19442848
Nature. 2002 Nov 14;420(6912):186-9
pubmed: 12432395
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Cytotechnology. 2007 May;54(1):35-48
pubmed: 19003016
Cytotechnology. 1995 Feb;17(1):21-6
pubmed: 22359206
Annu Rev Med. 2000;51:407-21
pubmed: 10774473
BMC Biotechnol. 2015 May 16;15:31
pubmed: 25981500
Expert Rev Vaccines. 2012 May;11(5):587-94
pubmed: 22827244
Appl Environ Microbiol. 2015 Jan;81(1):17-30
pubmed: 25304508
Biotechnol Prog. 2008 Jul-Aug;24(4):898-906
pubmed: 19194899
Appl Microbiol Biotechnol. 2015 Feb;99(4):1687-700
pubmed: 25472440
Vaccine. 2009 Oct 30;27(46):6460-3
pubmed: 19559113
Vaccine. 1999 Jul 30;17 Suppl 1:S3-10
pubmed: 10471173
PLoS One. 2014 Apr 03;9(4):e93865
pubmed: 24699760
Cytotechnology. 1996 Jan;22(1-3):225-37
pubmed: 22358933
Vaccine. 2018 May 24;36(22):3112-3123
pubmed: 28291648
Clin Exp Vaccine Res. 2017 Jan;6(1):61-66
pubmed: 28168175
J Biotechnol. 2006 Apr 20;122(4):463-72
pubmed: 16253368
Appl Environ Microbiol. 2010 Jul;76(13):4158-68
pubmed: 20435762
J Biol Eng. 2019 Oct 23;13:78
pubmed: 31666806
Appl Microbiol Biotechnol. 2013 Jun;97(12):5283-91
pubmed: 23553031
Radiat Res. 1988 Nov;116(2):305-12
pubmed: 3186938
Cytotechnology. 2006 Nov;52(3):199-207
pubmed: 19002878
J Biotechnol. 2020 Jan 10;307:139-147
pubmed: 31697977
Appl Environ Microbiol. 1998 Jun;64(6):2237-9
pubmed: 9603841
Science. 2014 Oct 3;346(6205):71-5
pubmed: 25278607
Sci Rep. 2018 Jul 9;8(1):10342
pubmed: 29985483
PLoS One. 2015 Apr 20;10(4):e0123562
pubmed: 25893827
J Biotechnol. 2012 Oct 31;161(3):328-35
pubmed: 22820340
J Biotechnol. 2005 Oct 17;120(1):72-82
pubmed: 16023241
Biochem J. 1988 Feb 15;250(1):1-8
pubmed: 2965576
Cell Host Microbe. 2015 Mar 11;17(3):295-300
pubmed: 25766291